Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

BQ.1.1 and XBB possess substitutions relative to BA.5 and BA.2, respectively, in the receptor-binding domain of their spike protein (appendix p 4), which is the major target for vaccines and therapeutic monoclonal antibodies (mAbs) for COVID-19. [...]we evaluated the neutralising ability of antibodi...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2023-01, Vol.23 (1), p.30-32
Main Authors: Uraki, Ryuta, Ito, Mutsumi, Furusawa, Yuri, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Adachi, Eisuke, Saito, Makoto, Koga, Michiko, Tsutsumi, Takeya, Yamamoto, Shinya, Otani, Amato, Kiso, Maki, Sakai-Tagawa, Yuko, Ueki, Hiroshi, Yotsuyanagi, Hiroshi, Imai, Masaki, Kawaoka, Yoshihiro
Format: Article
Language:English
Subjects:
Allergies
Antibodies
Clinical isolates
Coronaviruses
Correspondence
COVID-19
COVID-19 vaccines
Disease transmission
Humans
Immune Evasion
Infections
Infectious diseases
Influenza
Medical research
Monoclonal antibodies
mRNA
mRNA vaccines
Pathogenesis
Plasma
R&D
Research & development
Severe acute respiratory syndrome coronavirus 2
Spike protein
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BQ.1.1 and XBB possess substitutions relative to BA.5 and BA.2, respectively, in the receptor-binding domain of their spike protein (appendix p 4), which is the major target for vaccines and therapeutic monoclonal antibodies (mAbs) for COVID-19. [...]we evaluated the neutralising ability of antibodies in plasma from three different groups against BQ.1.1 and XBB clinical isolates: individuals (180–189 days after the third dose; n=20) who received three doses of the monovalent mRNA vaccine BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna), or both; individuals (33–57 days after the fourth dose; n=20) who received four doses of the monovalent mRNA vaccine BNT162b2 or mRNA-1273, or both; and individuals (29–89 days after the infection; n=10) who received three doses of monovalent BNT162b2 or mRNA-1273 before the BA.2 breakthrough infection. YK is supported by grants from the Center for Research on Influenza Pathogenesis (HHSN272201400008C) and from the Center for Research on Influenza Pathogenesis and Transmission (75N93021C00014), funded by the National Institute of Allergy and Infectious Disease; and by a Research Program on Emerging and Reemerging Infectious Diseases (JP21fk0108552 and JP21fk0108615), a Project Promoting Support for Drug Discovery (JP21nf0101632), the Japan Program for Infectious Diseases Research and Infrastructure (JP22wm0125002), and a grant (JP223fa627001) from the Japan Agency for Medical Research and Development.
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(22)00816-7